Does amikacin treatment cause subclinical hearing loss in patients with cystic fibrosis?

WOS: 000399044300046 PubMed: 28959562 Introduction: Aminoglycosides (AGs) have been widely used for potential life-threatening bacterial infections. Although AGs are well known for their ototoxic side effects, some AGs such as amikacin are considered less harmful to auditory functions; thus, auditory monitoring is mostly neglected during treatment with these drugs. Objective: To reflect the potential auditory hazards of repeated amikacin use on the patients with cystic fibrosis (CF). Method: 32CF patients with prior exposure to at least 3 courses of amikacin (the CF group) and 35 non CF patients visiting the outpatient clinic with any complaint other than hearing loss and no history of treatment with any AG( the control, or C group) were compared with pure-tone audiometry(PTA). The diagnosis of CF was made by Nanoduck sweat test. Results: The average age of the participants were 8.25 +/- 2.76 years in the CF group and 8.58 +/- 2.00 years in the C group (ranging from 5 to 13 years). 29 (43.28%) of the cases were female and 38 (56.71%) were male. Clinical SNHL(sensorineural hearing loss) was detected in 4 of the 32 subjects in the CF group. None of the subjects in the C group exhibited clinical SNHL. There was no statistically significant difference between the groups with regard to presence or absence of clinical SNHL (p > 0.05). However, hearing levels of the CF group were around 20 dB(decibel) HL(hearing loss), whereas hearing levels of the C group were around 5 dB. This difference was statistically significant for the pure tone averages of both all frequencies and speech frequencies (p < 0.05). Conclusion: Repetitive exposure to AGs can cause permanent, although mild, sensorineural hearing loss. For prevention, hearing status of the patient should be closely monitored and treatment of choice should be precisely tailored according to the audiological evaluation. This is especially important in patients with CF who frequently experience medical conditions necessitating AGs use. (C) 2016 Published by Elsevier Ireland Ltd.